FLT3
HGNC:3765 · 41 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Among patients with cytogenetically normal AML, the triple-positive mutation group (DNMT3A, NPM1, and FLT3-ITD) was the most frequent (n = 340, 29%), while DNMT3A co-occurrence with either FLT3 or NPM1 mutations alone was less common (4% and 9%, respectively).” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Additionally, we discuss emerging therapies, including CPX-351, hypomethylating agents (HMAs), targeted inhibitors (e.g., FLT3 and IDH1/2 inhibitors), and immunotherapies, while addressing the challenges of treatment resistance and relapse.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “It downregulates oncogenes, such as FLT3, Akt, ROS, and NF-κB, while protecting normal cells through upregulation of NRF-2, which enhances antioxidant production.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “The FMS-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase, plays a pivotal role in regulating cell survival, proliferation, and differentiation within the hematopoietic system.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Among our findings, we have identified that ALK, VHL, CTNNB1, EGFR, ERBB4, PDGFRA, KDR, SMO, ABL1, HRAS, ATM, HNF1A, FLT3, and RB1 mutations are common for psammomatous meningioma and angiomatous tumours.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “The molecular analysis results unveiled mutations in specific genes (FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS) targeted by nine microRNAs.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD+ Acute Myeloid Leukemia Cells.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3-ITD.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Probably pathogenic alterations occurred in 13/19 tumors (68.4%) and included variants in POLE (31.6%), CDKN2A (26%), NF1 (21%), BRCA2 (15.8%), SETD2 (5.3%), ATM (5.3%), FLT3 (5.3%), and ROS1 (5.3%).” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Additionally, a known intronic variant was identified in KDR and a known acceptor site splice variant in FLT3 (rs2491231) and a SNP in the 3 ' -UTR of the CSF1R gene (rs2066934) were also identified.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Age, gender, hematological data or molecular risk factors (FLT3 mutation/molecular fusion) exposed no significant differences across these two distinct ASXL1 expression groups (P > 0.05).” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Also, a 3'-UTR and a splice site acceptor site variant in CSF1R and FLT3 genes were found in this tumor.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML).” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “A number of concurrent and cooperating mutations clearly play a role in modulating the proliferative potential of cells, including mutations in KIT, FLT3, and possibly JAK2.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Eight synonymous mutations were found in FGFR3, PDGFRA, EGFR, RET, HRAS, FLT3, APC and SMAD4 genes.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “CASE PRESENTATION: A 28-years-old woman in the 26th week of gestation diagnosed with FLT3/ITD-mutated AML, complete remission was induced by Daunorubicin and Cytarabine, and subsequently with 5-azacytidine (75 mg/m2 daily for 7 days) with no fetal hematological or toxicity issues.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “BACKGROUND: Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Targeting FLT3 Mutations in Acute Myeloid Leukemia.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “BACKGROUND: Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “FLT3 Inhibitors for Treating Acute Myeloid Leukemia.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia?” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Cytogenetic and molecular analyses were performed in this case at the time of relapse to find out the chromosomal abnormalities and genetic abnormalities like FMS-like tyrosine kinase (FLT3) and nucleophosmin (NPM1) mutation.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “We sought to detect the nucleophosmin and FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutations among Iranian patients with AML and to assess the relationship between these mutations and the subtypes of the disease.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.” | 0.98 | hgnc_dict_v1 |
| gene | FLT3 | “Emerging evidence reveals that at the submicroscopic level, AML with normal cytogenetics may carry poor prognostic genetic lesions or "molecular signatures" as is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations that predict better risk as is the case with isolated NPM1 or CEBPA mutations.” | 0.98 | hgnc_dict_v1 |